Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of ageIntranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococciImmune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity.Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesClinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistancePneumococcal Capsules and Their Types: Past, Present, and FutureInterim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacementThe Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitisControlling antimicrobial resistance through targeted, vaccine-induced replacement of strainsCombinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23FPeptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.Pneumococcal septic arthritis after splenectomy in Felty's syndrome.Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniaeRapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies.Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesEvolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996).Streptococcus pneumoniae.Molecular characterization of the complete 23F capsular polysaccharide locus of Streptococcus pneumoniae.Pneumococcal Vaccination Strategies. An Update and Perspective.Antibiotic resistant Streptococcus pneumoniae.Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharidesInvasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance.Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in two Chilean citiesTransplacental transmission of serotype-specific pneumococcal antibodies in a Brazilian population.Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6BMolecular characterization of Streptococcus pneumoniae type 4, 6B, 8, and 18C capsular polysaccharide gene clustersInvasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995.Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoireVaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.Rethinking recommendations for use of pneumococcal vaccines in adults.Validation of a multiplex pneumococcal serotyping assay with clinical samples.Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate.Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae
P2860
Q24245934-07D8BA3E-17E4-4327-9E6D-E7CF27F826C3Q24548662-CD19178F-1B9D-4915-97EC-98573058FCE1Q24812252-75B77EEE-6064-4E98-9E16-7002FF09E6E0Q26746887-49A493BB-CE1E-459A-B60E-55A9E662E965Q26851961-5E6F06B0-5603-4489-AC1C-1DE898886FD5Q27006887-3F1E19BB-8818-49E2-B4EE-79A01421C0BFQ28069508-A6DA8646-8F72-41E0-8F0D-E5BD95E0055BQ28386753-F30BA3BB-2DFB-4B3B-920F-9031D1A46B63Q28485487-FE7B5441-017C-4F19-8FD8-C9FD16156E9EQ30658618-1F902F59-F805-4DED-AA36-BB969DED9043Q30864604-701533A9-80CE-4403-B175-D9BF651B3FAEQ33385276-2E28522B-A801-42B6-9658-A290D05C86BCQ33528283-BBA56A7E-D967-41BE-AAC2-A91B37363A93Q33592253-69DCB849-5C5D-4A38-93B6-1259EF5D8015Q33592895-66E4328B-FF7F-4D6E-BCED-870360ED37F6Q33595352-2A4F47AE-1C79-45CE-8D05-CC728BFC629FQ33603494-4110F743-F30D-490C-91E5-225F2C0A3AECQ33684439-9BD725F1-88CD-4B3C-8B77-539676A9297EQ33734675-C6A93377-C984-489A-911B-B5B5CE4086A4Q33737741-8F4C139A-5B4C-43A0-9B31-0BCD13BEC81EQ33772409-28AF7547-C617-45D4-A188-9322C5FC88EDQ33776122-48728F10-16E1-459A-A088-1DB819AD35C6Q33867137-BB27ED4F-AE52-4306-943F-231DFF88FA12Q33942204-68B7DBCD-259F-4FDC-88AA-99D894473040Q33975380-7D7B4E83-6FC2-489B-9439-E9264DD3F7D8Q33991415-725A13E2-F833-4BF3-BE7A-B7008F9455CCQ33997525-7466527E-08ED-448A-950B-E11E97E0BB4DQ33997738-4C9E8586-5F31-4595-B007-933D16D1E297Q33998938-E1039504-AB98-4DF2-BAEF-878F4623B675Q34000570-FA07A4B6-4F91-4F64-A04A-8C079F9A9679Q34003957-9F6627B2-D5D9-4E37-95BA-7538EC202CE5Q34005631-D9697829-4673-4B25-AC12-6A458993F004Q34006164-9D89D051-7215-4D41-95F7-EDA4E76ABE64Q34027404-AE874C6A-AECA-4849-A7A8-3DF036FD5650Q34111761-6DC7DFA7-CB31-4B20-A30B-AD7B518EDC77Q34113328-DEC90115-AE1A-41C5-9BF7-E52EA924B8A7Q34326459-D7944E1B-AD38-472B-8463-CF0E68C60405Q34345170-43A4863C-68FE-4C32-992C-360A685FD695Q34529116-8B2AC66F-2F3C-44B7-8A9C-AFB1744D1CE6Q34549615-F792B1EE-3855-4547-A30E-55E52E76FB22
P2860
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Considerations for formulating ...... -reactive types within groups.
@en
type
label
Considerations for formulating ...... -reactive types within groups.
@en
prefLabel
Considerations for formulating ...... -reactive types within groups.
@en
P2093
P356
P1476
Considerations for formulating ...... -reactive types within groups.
@en
P2093
Austrian R
Facklam RR
Henrichsen J
Rastogi SC
Robbins JB
Schiffman G
Tiesjema RH
P304
P356
10.1093/INFDIS/148.6.1136
P407
P577
1983-12-01T00:00:00Z